LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3061% below fair value
$2.96−0.38 (-11.23%)
Close on Nov 20, 2026Market cap $93.16MP/E –Yield –
LENZ Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $18.67M.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.21M | – |
| Q1 FY2026 | Mar 31, 2026 | $825.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $5.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
See a number that looks wrong?